Clinical Applications of Ligand Traps Targeting Activin Type II Receptors

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Activin type II receptors (ActRIIA/ACVR2A and ActRIIB/ACVR2B) are crucial mediators of TGF-β superfamily signaling.
• These receptors regulate critical biological processes including hematopoiesis, vascular homeostasis, and muscle regulation.
• Dysregulation of these pathways is implicated in various diseases.

Purpose of the Study:

• To review recent advancements in ligand trap therapies targeting activin type II receptors.
• To summarize the clinical applications and mechanisms of approved ligand trap agents.
• To highlight the therapeutic potential and future directions for these novel treatments.

Main Methods:

• Review of recent clinical trial data and preclinical studies on ligand trap therapies.
• Analysis of the molecular mechanisms of action for luspatercept and sotatercept.
• Evaluation of therapeutic efficacy in relevant disease models and patient populations.

Main Results:

• Luspatercept (ActRIIB-Fc) promotes erythropoiesis, showing efficacy in anemia associated with myelodysplastic syndromes and β-thalassemia.
• Sotatercept (ActRIIA-Fc) rebalances Smad signaling, improving vascular remodeling in pulmonary arterial hypertension.
• While not consistently effective for muscle mass increase, these agents represent significant progress in treating hematopoietic and vascular disorders.

Conclusions:

• Ligand trap therapies targeting activin type II receptors offer novel therapeutic strategies for specific hematological and vascular conditions.
• Further research is needed to optimize dosing, assess long-term safety, and explore combination therapies.
• These agents signify a breakthrough in managing diseases linked to TGF-β pathway dysregulation.